| Business Summary | | Axcan
Pharma
Inc.
is
a
North
American
pharmaceutical
company
within
the
field
of
gastroenterology.
Axcan
markets
a
broad
line
of
pharmaceutical
products
used
in
the
treatment
of
a
variety
of
gastrointestinal
diseases
and
disorders.
Axcan
carries
out
research
and
development
of
products
at
an
advanced
stage
of
development
that
it
acquires
or
licenses
from
third
parties.
Axcan
is
currently
developing
five
products
for
nine
indications,
eight
of
which
are
in
phase
II
or
III
studies,
and
one
for
which
a
New
Drug
Application
has
been
submitted
to
the
Food
and
Drug
Administration.
The
Company's
products
are
marketed
in
Canada
and,
through
its
subsidiary
Scandipharm
Inc.,
in
the
United
States.
Axcan
is
also
a
50%
owner
of
Althin
Biopharm
Inc.,
which
supplies
equipment
and
hemodialysis
products
for
patients
suffering
from
renal
failure.
In
addition,
Axcan
holds
a
50%
interest
in
Bonne
Sante
z.o.o.
and
CZET
Pharma,
two
companies
that
distribute
pharmaceutical
products
in
Poland. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Axcan
Pharma
Inc.
is
a
pharmaceutical
company
dedicated
to
the
research,
the
development,
the
production
and
the
marketing
of
innovative
products
in
the
field
of
gastroenterology.
For
the
nine
months
ended
6/30/01,
revenues
rose
21%
to
$76.1
million.
Net
income
from
continuing
operations
totaled
$7.1
million,
up
from
$2.5
million.
Revenues
reflect
an
increase
in
sales
of
PHOTOFRIN,
a
product
acquired
in
June
2000.
Net
income
also
reflects
lower
interest
expenses. | More
from
Market Guide: Significant
Developments |
| Officers | |
| Position | Leon Gosselin | Pres,
CEO, Director | Lisa Page Nelson | Managing
Director | Jacques Gauthier | Director,
Bus. Conultant | Colin Mallet | Director,
Bus. Consultant | David Mims | Exec.
VP, COO, Director |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|